BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment

Pallavi Madhiraju- March 8, 2024 0

In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted ... Read More

BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia

Raghuram Kadari- January 21, 2023 0

BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More